# A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

> **NCT07382739** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 34 (estimated)

## Conditions studied

- Phase 2
- Radiotherapy-Induced Immune Priming
- Elranatamab
- Relapsed Refractory Multiple Myeloma (RRMM)
- Extramedullary Disease in Multiple Myeloma
- Paramedullary Disease
- PMD

## Interventions

- **DRUG:** Elranatamab

## Key facts

- **NCT ID:** NCT07382739
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07382739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07382739, "A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT07382739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*